214 related articles for article (PubMed ID: 7690973)
1. Amantadine enhances dopamine and serotonin turnover in the MPTP model of Parkinson's disease.
Altagracia M; Rojas P; Kravzov J; Rios C
Proc West Pharmacol Soc; 1993; 36():289-91. PubMed ID: 7690973
[No Abstract] [Full Text] [Related]
2. Partially protective effect of amantadine in the MPTP model of Parkinson's disease.
Rojas P; Altagracia M; Kravsov J; Rios C
Proc West Pharmacol Soc; 1992; 35():33-5. PubMed ID: 1502234
[No Abstract] [Full Text] [Related]
3. Effects of L-deprenyl and amantadine in an MPTP-model of parkinsonism.
Rausch WD; Schallauer E; Chan WW; Riederer P; Weiser M
J Neural Transm Suppl; 1990; 32():269-75. PubMed ID: 1708404
[TBL] [Abstract][Full Text] [Related]
4. [Effect of acidic fibroblast growth factor on experimental parkinsonism and levels of dopamine and its metabolites in the striatum of mice of various ages].
Kucherianu VG; Kryzhanovskiĭ GN; Kudrin VS; Iurasov VV; Nikushkin EV; Zhigal'tsev IV
Biull Eksp Biol Med; 1999 May; 127(5):502-5. PubMed ID: 10399565
[No Abstract] [Full Text] [Related]
5. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Burns RS; LeWitt PA; Ebert MH; Pakkenberg H; Kopin IJ
N Engl J Med; 1985 May; 312(22):1418-21. PubMed ID: 2581135
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 1-methyl-4-(p-chlorophenyl)-1,2,3,6-tetrahydropyridine, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and p-chloroamphetamine as monoamine depletors.
Fuller RW; Hemrick-Luecke SK; Robertson DW
Res Commun Chem Pathol Pharmacol; 1985 Oct; 50(1):57-65. PubMed ID: 2417293
[TBL] [Abstract][Full Text] [Related]
7. Amine fluorescence histochemical investigation of the striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-induced parkinsonian mice.
Mizukawa K; Ogawa N; Sora YH
Res Commun Chem Pathol Pharmacol; 1988 Jan; 59(1):121-8. PubMed ID: 3258432
[TBL] [Abstract][Full Text] [Related]
8. Effects of nimodipine on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced depletions in the biogenic amine levels in mice.
Gerlach M; Russ H; Winker J; Witzmann K; Traber J; Stasch JP; Riederer P; Przuntek H
Arzneimittelforschung; 1993 Apr; 43(4):413-5. PubMed ID: 7684224
[TBL] [Abstract][Full Text] [Related]
9. MPTP treatment decreases striatal copper content in mice.
Alvarez-Vega R; Rios C; Rojas P; Kravsov J
Proc West Pharmacol Soc; 1992; 35():25-7. PubMed ID: 1502232
[No Abstract] [Full Text] [Related]
10. The development of amine substituted analogues of MPTP as unique tools for the study of MPTP toxicity and Parkinson's disease.
Johannessen JN; Savitt JM; Markey CJ; Bacon JP; Weisz A; Hanselman DS; Markey SP
Life Sci; 1987 Feb; 40(8):697-704. PubMed ID: 2433563
[TBL] [Abstract][Full Text] [Related]
11. Selective alterations of gene expression in mice induced by MPTP.
Xu Z; Cawthon D; McCastlain KA; Slikker W; Ali SF
Synapse; 2005 Jan; 55(1):45-51. PubMed ID: 15499605
[TBL] [Abstract][Full Text] [Related]
12. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
Gal S; Zheng H; Fridkin M; Youdim MB
J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
[TBL] [Abstract][Full Text] [Related]
13. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
[TBL] [Abstract][Full Text] [Related]
14. Serotonin and dopamine turnover after acute and chronic morphine administration.
Papeschi R; Theiss P; Herz A
Arzneimittelforschung; 1974 Jul; 24(7):1017-9. PubMed ID: 4408355
[No Abstract] [Full Text] [Related]
15. 2'-NH(2)-MPTP [1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine] depletes serotonin and norepinephrine in rats: a comparison with 2'-CH(3)-MPTP [1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine].
Unger EL; Mazzola-Pomietto P; Murphy DL; Andrews AM
J Pharmacol Exp Ther; 2002 Nov; 303(2):527-33. PubMed ID: 12388632
[TBL] [Abstract][Full Text] [Related]
16. The influence of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the levels of dopamine, serotonin and their metabolites in the caudate nucleus of the rat.
Russ H; Henning K; Eckhardt H; Przuntek H
Arzneimittelforschung; 1985; 35(2):481-2. PubMed ID: 2581589
[TBL] [Abstract][Full Text] [Related]
17. Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility.
Hofele K; Sedelis M; Auburger GW; Morgan S; Huston JP; Schwarting RK
Exp Neurol; 2001 Mar; 168(1):116-22. PubMed ID: 11170726
[TBL] [Abstract][Full Text] [Related]
18. Interleukine-1beta and interleukine-6 levels in striatum and other brain structures after MPTP treatment: influence of behavioral lateralization.
Shen YQ; Hebert G; Lin LY; Luo YL; Moze E; Li KS; Neveu PJ
J Neuroimmunol; 2005 Jan; 158(1-2):14-25. PubMed ID: 15589033
[TBL] [Abstract][Full Text] [Related]
19. Dopaminergic nervous transmission in Parkinson's disease.
Rinne UK; Sonninen V; Riekkinen P; Laaksonen H
Med Biol; 1974 Jun; 52(3):208-17. PubMed ID: 4371255
[No Abstract] [Full Text] [Related]
20. Endogenous analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: indoleamine derived tetrahydro-beta-carbolines as potential causative factors in Parkinson's disease.
Collins MA; Neafsey EJ; Cheng BY; Hurley-Gius K; Ung-Chhun NA; Pronger DA; Christensen MA; Hurley-Gius D
Adv Neurol; 1987; 45():179-82. PubMed ID: 3493625
[No Abstract] [Full Text] [Related]
[Next] [New Search]
